Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 GBX | -6.98% | -14.89% | -38.46% |
Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
Apr. 03 | FTSE 100 up thanks to US economic data | AN |
Sales 2022 | 49K 61.52K | Sales 2023 | 55K 69.05K | Capitalization | 17.33M 21.76M |
---|---|---|---|---|---|
Net income 2022 | -4M -5.02M | Net income 2023 | -5M -6.28M | EV / Sales 2022 | 237 x |
Net cash position 2022 | 4.57M 5.74M | Net cash position 2023 | 2.36M 2.96M | EV / Sales 2023 | 272 x |
P/E ratio 2022 |
-3.18
x | P/E ratio 2023 |
-3.18
x | Employees | 43 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.93% |
1 day | -6.98% | ||
1 week | -14.89% | ||
Current month | +48.15% | ||
1 month | +48.15% | ||
3 months | -21.57% | ||
6 months | -42.03% | ||
Current year | -38.46% |
Managers | Title | Age | Since |
---|---|---|---|
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Chris Yates
BRD | Director/Board Member | 50 | 18-08-21 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 18-04-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 5 | -6.98% | 506,281 |
24-04-26 | 5.375 | -4.44% | 1,268,206 |
24-04-25 | 5.625 | -8.16% | 3,024,427 |
24-04-24 | 6.125 | +8.89% | 5,461,201 |
24-04-23 | 5.625 | -4.26% | 744,960 |
Delayed Quote London S.E., April 29, 2024 at 11:35 am EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.46% | 9.58M | |
-12.42% | 19.08B | |
-46.59% | 2.65B | |
+17.50% | 1.87B | |
-0.58% | 1.61B | |
+25.36% | 1.21B | |
-8.67% | 1.02B | |
-21.91% | 905M | |
-4.42% | 716M | |
-17.51% | 682M |
- Stock Market
- Equities
- GDR Stock